Search Results

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), Connectyx announced today the addition of three industry veterans to the company’s management team.

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced that it has filed financial results for the fiscal year ended December 31, 2020.

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies.

Initial Biotechnology Portfolio Includes Therapies for Glioblastoma and Late Stage Rabies

The licensed patent rights include US Patent No. 10,548,987 issued February 02, 2020 (Patent Application No. 15/747,620 filed January 25, 2018).